Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Redmile Group LLC

Redmile Group LLC lessened its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 3.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,280,981 shares of the company's stock after selling 142,635 shares during the quarter. Nurix Therapeutics accounts for approximately 5.7% of Redmile Group LLC's holdings, making the stock its 2nd largest holding. Redmile Group LLC owned 6.04% of Nurix Therapeutics worth $96,194,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of NRIX. Amalgamated Bank boosted its stake in shares of Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company's stock worth $49,000 after acquiring an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock worth $54,000 after buying an additional 559 shares during the last quarter. Quest Partners LLC boosted its holdings in shares of Nurix Therapeutics by 21.3% during the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after buying an additional 1,312 shares during the period. ClariVest Asset Management LLC grew its stake in Nurix Therapeutics by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company's stock valued at $1,318,000 after buying an additional 1,766 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company's stock valued at $95,000 after acquiring an additional 3,424 shares during the period.

Nurix Therapeutics Stock Down 3.7 %

Shares of NASDAQ:NRIX traded down $0.76 during midday trading on Thursday, hitting $20.06. The stock had a trading volume of 752,769 shares, compared to its average volume of 900,590. The company's 50-day moving average price is $23.79 and its 200-day moving average price is $21.90. Nurix Therapeutics, Inc. has a fifty-two week low of $7.65 and a fifty-two week high of $29.56. The company has a market capitalization of $1.42 billion, a P/E ratio of -6.89 and a beta of 2.11.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Friday, October 11th. The company reported ($0.67) EPS for the quarter, meeting the consensus estimate of ($0.67). The business had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. Research analysts expect that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $24.28, for a total transaction of $86,096.88. Following the sale, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at approximately $818,818.72. The trade was a 9.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,437 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $83,519.10. Following the completion of the transaction, the insider now directly owns 50,670 shares of the company's stock, valued at approximately $1,231,281. The trade was a 6.35 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,401 shares of company stock valued at $437,453. Corporate insiders own 7.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on NRIX shares. Robert W. Baird initiated coverage on Nurix Therapeutics in a report on Friday, September 6th. They set an "outperform" rating and a $26.00 price objective for the company. Royal Bank of Canada reduced their price target on Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. HC Wainwright increased their price objective on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Stephens reissued an "overweight" rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Monday, October 14th. Finally, Needham & Company LLC restated a "buy" rating and issued a $29.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.40.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.